Abstract
Background: Quinacrine is an older antimalarial drug that remains in use for a variety of illnesses including treatment-resistant giardiasis.
Case Presentation: We report a patient with no prior psychiatric history who developed mild, prodromal psychiatric symptoms when treated with quinacrine for treatment-resistant giardiasis. Symptoms resolved when the drug was stopped, recurred with greater severity (requiring involuntary psychiatric hospitalization) when restarted and promptly resolved again when the drug was finally stopped.
Conclusion: Although quinacrine remains in use today, providers may be unaware of its potential for serious neuropsychiatric toxicity.
Keywords: Quinacrine, quinolines, psychosis, adverse drug reaction, case report, giardiasis.
Current Drug Safety
Title:A Case of Quinacrine-induced Psychosis: Case Report
Volume: 16 Issue: 3
Author(s): Anangamanjari Pedapudi*, Jonathan Stewart and Ankita Patel
Affiliation:
- Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine, Tampa, FL33612,United States
Keywords: Quinacrine, quinolines, psychosis, adverse drug reaction, case report, giardiasis.
Abstract:
Background: Quinacrine is an older antimalarial drug that remains in use for a variety of illnesses including treatment-resistant giardiasis.
Case Presentation: We report a patient with no prior psychiatric history who developed mild, prodromal psychiatric symptoms when treated with quinacrine for treatment-resistant giardiasis. Symptoms resolved when the drug was stopped, recurred with greater severity (requiring involuntary psychiatric hospitalization) when restarted and promptly resolved again when the drug was finally stopped.
Conclusion: Although quinacrine remains in use today, providers may be unaware of its potential for serious neuropsychiatric toxicity.
Export Options
About this article
Cite this article as:
Pedapudi Anangamanjari *, Stewart Jonathan and Patel Ankita , A Case of Quinacrine-induced Psychosis: Case Report, Current Drug Safety 2021; 16 (3) . https://dx.doi.org/10.2174/1574886315666201005103142
DOI https://dx.doi.org/10.2174/1574886315666201005103142 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
S100A9 as a Pharmacological Target Molecule in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Biosynthesis of Peptide Hormones Derived from Precursor Sequences
Current Medicinal Chemistry Functional Evaluation of Neural Stem Cell Differentiation by Single Cell Calcium Imaging
Current Stem Cell Research & Therapy Inactivation of PDH can Reduce Anaplastic Thyroid Cancer Cells’ Sensitivity to Artemisinin
Anti-Cancer Agents in Medicinal Chemistry Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Role of Environmental Contaminants in the Etiology of Alzheimer’s Disease: A Review
Current Alzheimer Research Extracellular Citrate in Health and Disease
Current Molecular Medicine Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Current Cancer Therapy Reviews Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomic Approaches to Osteoporosis: 2005 Update
Current Pharmacogenomics Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial [Hot topic: Membrane Estrogen Receptors (Guest Editor: Paul J. Davis)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Gynecomastia in Infants, Children, and Adolescents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cloning, Expression and Characterization of Mouse (Mus musculus) Nicotinamide 5-Mononucleotide Adenylyltransferase-2
Medicinal Chemistry Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis
Recent Patents on Anti-Cancer Drug Discovery